Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
HIV-infection/AIDS
Interventions
DRUG

Triptolide Wilfordii

In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.

DRUG

Placebo Oral Tablet

In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.

Trial Locations (7)

100069

Beijing YouAn Hospital, Capital Medical University, Beijing

100191

Beijing Ditan Hospital, Capital Medical University, Beijing

150001

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

310023

Xixi Hospital of Hangzhou, Hangzhou

350025

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

450015

The Sixth People's Hospital of Zhengzhou, Zhengzhou

510060

The Eighth People's Hospital of Guangzhou, Guangzhou

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT03403569 - Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection | Biotech Hunter | Biotech Hunter